SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing intense volatility and trading volume as community members debate whether the rally is a legitimate breakout driven by upcoming music festival partnerships or a manipulated pump-and-dump scheme. Investors remain sharply divided, with some highlighting the project's real-world event utility and future roadmap as catalysts for growth, while others express concerns over high wallet concentration and potential regulatory investigation.

Aave is a decentralized money market protocol where users can lend and borrow cryptocurrency across 20 different assets as collateral. The protocol has a native token called AAVE, which is also a governance token that lets the community decide the direction of the protocol in a collective manner. Lenders can&nbsp;earn interest by providing liquidity to the market, while borrowers can borrow by collateralizing their cryptoassets to take out loans from the liquidity pools.

AAVE

AAVE is generating significant community buzz as traders weigh its potential as an undervalued DeFi leader against broader market volatility and governance-related news. While some participants are actively accumulating on dips in anticipation of a parabolic breakout, others remain focused on technical support levels and ongoing debates regarding its long-term stability compared to other lending protocols.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is gaining significant traction as investors reconnect with its 2011 origin as the original parody token, with community members highlighting its deep historical roots, locked supply, and organic narrative as drivers for potential long-term growth. While some skeptics dismiss it as a joke, proponents are actively comparing it to early memecoin successes and emphasizing its status as a foundational piece of crypto culture that is currently undergoing a massive resurgence.

Procure ETF Trust II - Procure Space ETF

The Procure Space ETF ($UFO) is attracting significant community attention as investors position themselves for the potential IPO of SpaceX and the broader expansion of the commercial space economy. While some community members appreciate the ETF for its broad exposure to industry leaders, others are debating whether its diverse holdings truly constitute a 'pure play' on space, leading to discussions about alternative investment strategies.

Daddy Darth Vader

The community is engaged in a speculative "Daddy Wars" narrative involving DARTH, SIDIOUS, and MAULCOIN, with participants actively debating the leadership and future trajectory of these low market cap tokens. Supporters are highlighting aggressive community-driven marketing and token giveaways, while skeptics warn of volatility and the risks inherent in such nano-cap assets.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is trending due to a significant policy shift following a new executive order that accelerates FDA review pathways for psychedelic-based therapies, including LSD. Investors are actively debating the potential for a sector-wide re-rating and identifying candidates for future M&A, as Definium remains in focus with multiple Phase 3 trial readouts scheduled throughout the year.

Horizon Quantum Holdings Ltd. engages in the development of software tools. The company is headquartered in Singapore.

Horizon Quantum Holdings Ltd. - Ordinary Shares - Class A

Horizon Quantum is capturing market attention as a low-float, software-focused quantum computing play that investors are comparing to early-stage operating system developers. Community discussion is centered on its strategic partnerships with major industry players and its potential to benefit from a rotation of liquidity into the quantum sector.

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment focuses on Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck in 2013 and is headquartered in San Francisco, CA.

Twist Bioscience Corp

Twist Bioscience is generating strong buzz as investors weigh its robust revenue growth and expanding market reach against skepticism regarding the firm's path to consistent profitability. The community is actively debating the company's long-term potential as a foundational "picks and shovels" provider for the biotechnology sector while closely monitoring insider trading activity and recent revenue guidance upgrades.

SuRo Capital Corp. operates as a publicly traded investment fund. It seeks to invest in a broad range of sectors and industries as well as to provide investors with access to such companies through its publicly traded common stock. The company was founded by Mark David Klein on September 17, 2010 and is headquartered in New York, NY.

SuRo Capital Corp

SuRo Capital Corp.

SuRo Capital is trending as investors focus on its concentrated stake in high-growth AI infrastructure companies like CoreWeave and OpenAI, with community sentiment bolstered by potential IPO activity and the firm's portfolio value relative to its NAV. Traders are actively discussing the stock's significant discount to underlying asset value and the impact of upcoming liquidity events, often drawing comparisons to other venture-focused investment vehicles.

Daddy Darth Sidious

The community is actively engaged in a speculative race between SIDIOUS, DARTH, and MAULCOIN, with participants discussing potential market rotations and monitoring nano-cap price action. Traders are sharing strategies for entry points and social sentiment as they speculate on the token's trajectory relative to these competing projects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Delcath Systems (NASDAQ:DCTH) Stock Price Up 0.3% - Time to Buy?

Delcath Systems (NASDAQ:DCTH) Shares Up 0.3% - Should You Buy...

Implied Volatility Surging for Delcath Systems Stock Options

Investors need to pay close attention to DCTH stock based on the movements in the options market lately.

Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMOEURACAN Clinical Practice Guidelines for Uveal Melanoma

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on liver-directed cancer therapies, today announced that its proprietary CHEMOSAT Hepatic Delivery System for...

Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will attend the Society of Interventional Radiology...

Delcath Systems, Inc. (NASDAQ:DCTH) Given Average Rating of "Moderate Buy" by Brokerages

Shares of Delcath Systems, Inc. (NASDAQ:DCTH - Get Free Report) have earned an average recommendation of "Moderate Buy" from the six ratings firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating and five have issued a buy ra...

Divisadero Street Capital Management LP Invests $5.12 Million in Delcath Systems, Inc. $DCTH

Divisadero Street Capital Management LP purchased a new position in Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with...

Propel Bio Management LLC Buys 212,457 Shares of Delcath Systems, Inc. $DCTH

Propel Bio Management LLC grew its stake in shares of Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) by 94.0% during the third quarter, according to its most recent filing with the Securities and...

Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology

Delcath Systems, Inc. (Nasdaq: DCTH), (Delcath or the Company) an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of...

FY2029 EPS Forecast for Delcath Systems Decreased by Analyst

Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) - Equities researchers at HC Wainwright dropped their FY2029 EPS estimates for shares of Delcath Systems in a note issued to investors on Monday...

Delcath Systems, Inc. (NASDAQ:DCTH) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Delcath Systems, Inc. (NASDAQ:DCTH - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six research firms that are currently covering the company, MarketBeat...

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded on August 5, 1988 and is headquartered in Queensbury, NY.

DCTH
Delcath Systems Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest DCTH News

DCTHDelcath Systems Inc